Abstract
STAT3 is frequently overexpressed and constitutively activated by tyrosine phosphorylation during malignant transformation. Despite the clear importance of STAT3 in cell proliferation and survival in diverse human cancers, its possible contribution to tumor cell adhesion, motility and invasion remains hypothetical. We therefore compared the transforming properties of STAT3wt, its constitutively activated dimeric form STAT3C, and the dominant negative mutant STAT3-Y705F in human colorectal HCT8/S11 cancer cells. Both STAT3wt and STAT3C exert a permissive action to the proinvasive activity of the scatter factor HGF in HCT8/S11 cells. In contrast, the monomeric and cytoplasmic mutant Y705F induces a constitutive invasive phenotype through Wnt/Rho-independent and EGFR/PI3-kinase-dependent pathways. Accordingly, Y705F decreases cell–cell homotypic adhesions, and increases cell motility and scattering, as well as lamellipodia-type cellular extensions. STAT3-Y705F-transfected HCT8/S11 cells display an increased tyrosine phosphorylation of the cell–cell adhesion regulator β-catenin and its dissociation from the invasion suppressor E-cadherin at cell–cell contacts. Our data imply that both invasion promoter and repressor genes are controlled by the canonical STAT3 transcription pathways. Disruption of this cascade by Y705F reveals the proinvasive potential of altered forms of STAT3 as a persistent signaling adaptor in cytokine/transforming growth factor receptor scaffolds and oncogenic pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, Wymann MP and Gespach C . (2000). FASEB J., 14, 2329–2338.
Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM . (1998). Nat. Med., 4, 923–928.
Balsamo J, Leung T, Ernst H, Zanin MK, Hoffman S and Lilien J . (1996). J. Cell Biol., 134, 801–813.
Barbier M, Attoub S, Calvez R, Laffargue M, Jarry A, Mareel M, Altruda F, Gespach C, Wu D, Lu B, Hirsch E and Wymann MP . (2001). Nature, 413, 796.
Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM and Birchmeier W . (1993). J. Cell Biol., 120, 757–766.
Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C and Comoglio PM . (1998). Nature, 391, 285–288.
Boterberg T, Vennekens KM, Thienpont M, Mareel MM and Bracke ME . (2000). Cell Adhes. Commun., 7, 299–310.
Bowman T, Garcia R, Turkson J and Jove R . (2000). Oncogene, 19, 2474–2488.
Brabletz T, Jung A, Dag S, Hlubek F and Kirchner T . (1999). Am. J. Pathol., 155, 1033–1038.
Bracke ME, Boterberg T, Bruyneel E and Mareel M . (2000). Collagen Invasion Assay. Humana Press edn: Totowa, NJ, USA, 58, 81–89.
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell Jr JE . (1999). Cell, 98, 295–303.
Cao X, Tay A, Guy GR and Tan YH . (1996). Mol. Cell. Biol., 16, 1595–1603.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R . (1999). Immunity, 10, 105–115.
Chung J, Uchida E, Grammer TC and Blenis J . (1997). Mol. Cell. Biol., 17, 6508–6516.
Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM . (1999). Oncogene, 18, 2883–2891.
Daniel JM and Reynolds AB . (1997). BioEssays, 19, 883–891.
Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B and Leonard EJ . (2001). Mol. Cell. Biol., 21, 5857–5868.
Darnell Jr JE, Kerr IM and Stark GR . (1994). Science, 264, 1415–1421.
Eastman Q and Grosschedl R . (1999). Curr. Opin. Cell Biol., 11, 233–240.
Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM and Kerbel RS . (1999). Oncogene, 18, 1023–1032.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D and Birchmeier W . (1991). J. Cell Biol., 113, 173–185.
Goiot H, Attoub S, Kermorgant S, Laigneau JP, Lardeux B, Lehy T, Lewin MJ and Bado A . (2001). Gastroenterology, 121, 1417–1427.
Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ . (1998). J. Clin. Invest., 102, 1385–1392.
Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y and Kim JD . (2000). Proc. Natl. Acad. Sci. USA, 97, 4227–4232.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW . (1998). Science, 281, 1509–1512.
Hellyer NJ, Cheng K and Koland JG . (1998). Biochem. J., 333, 757–763.
Hiscox S and Jiang WG . (1999). J. Cell Sci., 112, 3081–3090.
Hoschuetzky H, Aberle H and Kemler R . (1994). J. Cell. Biol., 127, 1375–1380.
Huang M, Page C, Reynolds RK and Lin J . (2000). Gynecol. Oncol., 79, 67–73.
Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH, Yu DY and Shong M . (2003). Mol. Endocrinol., 17, 1155–1166.
Ichiba M, Nakajima K, Yamanaka Y, Kiuchi N and Hirano T . (1998). J. Biol. Chem., 273, 6132–6138.
Ilan N, Mahooti S, Rimm DL and Madri JA . (1999). J. Cell Sci., 112, 3005–3014.
Irby RB and Yeatman TJ . (2002). Cancer Res., 62, 2669–2674.
Kim K and Lee KY . (2001). Cell. Biol. Int., 25, 421–427.
Kinch MS, Clark GJ, Der CJ and Burridge K . (1995). J. Cell Biol., 130, 461–471.
Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F and Behrmann I . (1999). Oncogene, 18, 3742–3753.
Kotelevets L, Noe V, Bruyneel E, Myssiakine E, Chastre E, Mareel M and Gespach C . (1998). J. Biol. Chem., 273, 14138–14145.
Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM and Mendel DB . (2003). Mol. Cancer Ther., 2, 461–469.
Matsui T, Kinoshita T, Hirano T, Yokota T and Miyajima A . (2002). J. Biol. Chem., 277, 36167–36173.
Minami M, Inoue M, Wei S, Takeda K, Matsumoto M, Kishimoto T and Akira S . (1996). Proc. Natl. Acad. Sci. USA, 93, 3963–3966.
Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M and Hirano T . (1996). EMBO J., 15, 3651–3658.
Ning ZQ, Li J, McGuinness M and Arceci RJ . (2001). Oncogene, 20, 4528–4536.
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H . (2002). Oncogene, 21, 2000–2008.
Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, Okabe M, Yamauchi-Takihara K, Kawase I and Kishimoto T . (2001). J. Biol. Chem., 14, 14.
Ozawa M, Baribault H and Kemler R . (1989). EMBO J., 8, 1711–1717.
Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C and Heim MH . (2000). Int. J. Cancer, 85, 720–725.
Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W and Yang CH . (1997). Science, 276, 1418–1420.
Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A . (2001). Endocr. Relat. Cancer, 8, 11–31.
Price JT, Wilson HM and Haites NE . (1996). Eur. J. Cancer, 32A, 1977–1982.
Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD and Fidler IJ . (1995). Clin. Cancer Res., 1, 19–31.
Ridley AJ and Hall A . (1992). Cell, 70, 389–399.
Rodrigues S, Attoub S, Nguyen QD, Bruyneel E, Rodrigue C, Westley BR, May FEB, Thim L, Mareel M, Emami S and Gespach C . (2003). Oncogene, 22, 4488–4497.
Rosenblum CI, Tota M, Cully D, Smith T, Collum R, Qureshi S, Hess JF, Phillips MS, Hey PJ, Vongs A, Fong TM, Xu L, Chen HY, Smith RG, Schindler C and Van der Ploeg LH . (1996). Endocrinology, 137, 5178–5181.
Roura S, Miravet S, Piedra J, Garcia de Herreros A and Dunach M . (1999). J. Biol. Chem., 274, 36734–36740.
Salomon DS, Brandt R, Ciardiello F and Normanno N . (1995). Crit. Rev. Oncol. Hematol., 19, 183–232.
Sartor CI, Dziubinski ML, Yu CL, Jove R and Ethier SP . (1997). Cancer Res., 57, 978–987.
Shen Y, Devgan G, Darnell JE and Bromberg JF . (2001). Proc Natl Acad Sci USA, 98, 1543–1548.
Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D and Darnell Jr JE . (1994). Cell, 76, 821–828.
Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH and Guan KL . (2000). Science, 290, 144–147.
Spiotto MT and Chung TD . (2000). Prostate, 42, 186–195.
Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP and Jove R . (1998). Mol. Cell. Biol., 18, 2545–2552.
Turner T, Chen P, Goodly LJ and Wells A . (1996). Clin. Exp. Metast., 14, 409–418.
Uttamsingh S, Zong CS and Wang LH . (2003). J. Biol. Chem., 278, 18798–18810.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM . (2002). Nature, 419, 624–629.
Vermeulen SJ, Bruyneel EA, Bracke ME, De Bruyne GK, Vennekens KM, Vleminckx KL, Berx GJ, van Roy FM and Mareel MM . (1995). Cancer Res., 55, 4722–4728.
Vleminckx K, Vakaet Jr L, Mareel M, Fiers W and van Roy F . (1991). Cell, 66, 107–119.
Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens J and Grandis JR . (2003). J. Biol. Chem., 278, 31574.
Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, Platt A, Gilmer TM, Fu XY and Chin YE . (2002). J. Biol. Chem., 277, 30716–30723.
Xie H, Pallero MA, Gupta K, Chang P, Ware MF, Witke W, Kwiatkowski DJ, Lauffenburger DA, Murphy-Ullrich JE and Wells A . (1998). J. Cell Sci., 111, 615–624.
Yarden Y . (2001). Eur. J. Cancer, 37, S3–S8.
Yoshioka K, Matsumura F, Akedo H and Itoh K . (1998). J. Biol. Chem., 273, 5146–5154.
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J and Jove R . (1995). Science, 269, 81–83.
Zhang X, Wrzeszczynska MH, Horvath CM and Darnell Jr JE . (1999). Mol. Cell. Biol., 19, 7138–7146.
Zhang YW, Wang LM, Jove R and Vande Woude GF . (2002). Oncogene, 21, 217–226.
Zhong Z, Wen Z and Darnell Jr JE . (1994). Science, 264, 95–98.
Acknowledgements
We are grateful to Drs S Roche, I Dusanter, L Pfeffer, J Darnell, L Debussche, LM Matrisian, P Polakis, C Caron, G Flatau and P Comoglio for providing reagents. This work was supported by INSERM, a post-doctoral fellowship from AstraZeneca (to SA), Research Grants from the Association de la Recherche sur le Cancer (ARC), the Groupement des Entreprises Françaises dans la Lutte Contre le Cancer France (to SA and CG), the Belgische Federatie tegen Kanker, the FORTIS Verzekeringen and the Fund for Scientific Research Flanders (Brussels, Belgium). CR is a PhD student supported by the French Ministry of the Scientific Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rivat, C., Wever, O., Bruyneel, E. et al. Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell–cell adhesion complexes. Oncogene 23, 3317–3327 (2004). https://doi.org/10.1038/sj.onc.1207437
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207437
Keywords
This article is cited by
-
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity
Oncogene (2014)
-
Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
British Journal of Cancer (2011)
-
Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon
Oncogene (2007)